Aethlon Medical (NASDAQ:AEMD) Announces Quarterly Earnings Results, Beats Expectations By $2.86 EPS

Aethlon Medical (NASDAQ:AEMD) posted its quarterly earnings data on Wednesday. The medical equipment provider reported $0.40 EPS for the quarter, topping the consensus estimate of ($2.46) by $2.86, FiscalAI reports.

Aethlon Medical Stock Up 4.1%

Aethlon Medical stock traded up $0.08 during trading hours on Wednesday, hitting $2.02. The stock had a trading volume of 602,662 shares, compared to its average volume of 343,914. The stock has a market capitalization of $3.17 million, a P/E ratio of -0.14 and a beta of 1.49. Aethlon Medical has a 12-month low of $1.36 and a 12-month high of $27.40. The stock’s 50-day moving average price is $2.23 and its 200-day moving average price is $2.51.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Aethlon Medical stock. Citadel Advisors LLC bought a new stake in shares of Aethlon Medical, Inc. (NASDAQ:AEMD) in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 95,084 shares of the medical equipment provider’s stock, valued at approximately $71,000. Citadel Advisors LLC owned 36.57% of Aethlon Medical at the end of the most recent quarter. Institutional investors and hedge funds own 1.99% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Aethlon Medical in a research note on Monday, April 20th. One equities research analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Reduce”.

About Aethlon Medical

Aethlon Medical, Inc (NASDAQ: AEMD) is a clinical‐stage biotechnology company focused on developing novel immunotherapeutic medical devices to address life‐threatening diseases. The company’s lead product candidate, the Hemopurifier®, is an extracorporeal affinity device designed to remove circulating viruses and immunosuppressive exosomes from the bloodstream. By targeting glycosylated pathogens and exosomes, Aethlon aims to restore immune function and improve patient outcomes in oncology and infectious disease settings.

The Hemopurifier platform leverages proprietary lectin affinity technology to selectively bind and eliminate harmful particles without depleting healthy blood components.